Gabapentinoids: Sponsored Trials for Off-label Use - Softcover

Inhaltsangabe

This review of pharmaceutical data and clinical trial archives, provides an unprecedented access to regulatory decisions that have shaped current medical guidelines and prescribing habits.The documents that were reviewed on clinical trials of gabapentinoids indicate a clear and deliberate pattern of reporting biases, including but not limited to publication bias, selective outcome reporting, selective analyses, multiple publication, location bias, time lag bias, and citation bias. There is extensive evidence of reframing and spin to make negative results appear positive; ghost authorship; and bias in study design. These biases render information about pregabalin’s effectiveness and safety, in particular, as disseminated in the published literature, as stand-alone reports of trials, or as included in systematic reviews, scientifically invalid.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.